Genzyme, a fully owned subsidiary of Sanofi SA (ADR) (NYSE:SNY) and the manufacturer of the drug, said that it understood that the FDA’s decision to reject Lemtrada was based on the design of the completed Phase 3 trials it reviewed. The decision against approval was based on two studies, CARE-MS I and CARE-MS II, which compared Lemtrada’s effectiveness in reducing relapses to beta interferon (the standard drug used by relapsed MS patients.) Sanofi SA (ADR) (NYSE:SNY) stock opened at $51.28 in last session, and closed at $51.08, while the day range of SNY stock is $50.94 – $51.33. The stock showed a negative weekly performance of -4.75%.
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations. GlaxoSmithKline plc (ADR) (NYSE:GSK) stock opened at $52.88, in last session and closed at $52.73, by losing -0.64%. The 52 week range of the stock is $43.68 – $54.00. Company’s market capitalization is $129.42billion.
Cameron International Corp. (NYSE:CAM) was downgraded by RBC Capital from a “top pick” rating to an “outperform” rating in a research note issued on Wednesday, TheFlyOnTheWall.com reports. Cameron International Corporation (NYSE:CAM) stock decreased -0.03% and finished the last session at $58.85. The EPS of the stock remained 2.82. Company’s market capitalization is $14.00 billion.
AZZ Incorporated (NYSE:AZZ) lost 13.95% yesterday as the company has reduced its fiscal 2014 outlook below Wall Street’s expectations. The 2014 earnings guidance has been lowered to $2.30 – $2.40 per share as compared to the prior estimate of $2.45 – $2.65 per share. Analysts expect annual earnings per share of $2.77. AZZ Incorporated (NYSE:AZZ) stock opened the session at $44.00, and closed the session at $40.39. The 52 week range of the stock remained $34.61 – $49.64 and the day range was $40.30 – $44.00.